Abstract:TL1A and its functional receptor DR3 are members of the TNF/TNFR superfamilies of proteins. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. DR3 was also found to be highly expressed by innate lymphoid cells (ILCS), which respond to stimulation by TL1A. Several recent studies with transgenic and knockout mice as well as neutralizing or agonistic antibodies for these two proteins, have clearly shown that TL1A/DR3 are important mediators of several chronic immunological disorders, including Inflammatory Bowel Disease (IBD). TL1A and DR3 are abundantly localized at inflamed intestinal areas of patients with IBD and mice with experimental ileitis or colitis and actively participate in the immunological pathways that underlie mucosal homeostasis and intestinal inflammation. DR3 signaling has demonstrated a dichotomous role in mucosal immunity. On the one hand, during acute mucosal injury it exerts protective functions by ameliorating the severity of acute inflammatory responses and facilitating tissue repair. On the other hand, it critically participates in the pro-inflammatory pathways that underlie chronic inflammatory responses, such as those that take place in IBD. These effects are mediated through modulation of the relative mucosal abundance and function of Th1, Th2, Th17, Th9, and Treg lymphocytes, but also of all types of ILCs. Recently, an important role was demonstrated for TL1A/DR3 as potential mediators of intestinal fibrosis that is associated with the presence of gut inflammation. These accumulating data have raised the possibility that TL1A/DR3 pathways may represent a valid therapeutic target for chronic immunological diseases. Nevertheless, applicability of such a therapeutic approach will greatly rely on the net result of TL1A/DR3 manipulation on the various cell populations that will be affected by this approach.

Toll-like receptor 3 involvement in vascular function

Toll-Like Receptor 3 in Cardiovascular Diseases

Toll-like Receptor 3 and Tumor Immunity

Toll-like receptor 3 and its signaling pathway

Toll-Like Receptors: New Players in Myocardial Ischemia/Reperfusion Injury

A novel role of CCN3 in regulating endothelial inflammation

Toll-like Receptor 2 in Promoting Angiogenesis after Acute Ischemic Injury.

Transient receptor potential canonical type 3 channels: Interactions, role and relevance - A vascular focus

The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease.

To aggregate, or not to aggregate? considerations in the design and application of polymeric thermally-responsive nanoparticles.

The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease

TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity

Vessel-specific Toll-like receptor profiles in human medium and large arteries

[Human immunoglobulins].

Translationally controlled tumor protein is a target of tumor reversion.

TRAF3-interacting JNK-activating Modulator Promotes Inflammation by Stimulating Translocation of Toll-like Receptor 4 to Lipid Rafts

Thrombomodulin as a Physiological Modulator of Intravascular Injury

Effect of Newborn Resuscitation Training on Health Worker Practices in Pumwani Hospital, Kenya

Toll-Like Receptor 3 Signaling Contributes to Regional Neutrophil Recruitment in Cultured Human Glomerular Endothelial Cells

Increased expression of Toll-like receptor 3 in intrahepatic biliary epithelial cells at sites of ductular reaction in diseased livers

Role Of The Signal Transducer And Activator Of Transcription 3 Protein In The Proliferation Of Vascular Smooth Muscle Cells